- In April 2025, NeuroOne Medical Technologies Corporation submitted its OneRF®Trigeminal Nerve Ablation System for FDA 510(k) clearance. The system is designed to treat trigeminal neuralgia using a minimally invasive, single-probe RF solution that offers more targeted pain management. This development marks a significant step in expanding RF ablation applications for craniofacial pain relief
- In December 2024, AngioDynamics received FDA 510(k) clearance for its NanoKnife System for prostate tissue ablation. Clinical results showed an 84% negative in-field biopsy rate at 12 months with preservation of urinary continence, underscoring the safety and precision of this nonthermal ablation technology. This approval further expands the therapeutic reach of irreversible electroporation
